Good news this month for consumers who are sick of those glabellar lines—the so-called ‘elevens’ that nestle like vertical divots between the eyebrows. The FDA has approved a new injectible called XEOMIN, the latest entry in the neurotoxin race that so far includes BOTOX and Dysport. XEOMIN, made by pharmaceutical giant Merz, has received the FDA go-ahead for the temporary removal of severe glabellar lines. The approval came after two multicenter clinical trials involving 547 healthy adults showed a great improvement in the appearance of those vertical indentations in 30 days, as compared to a placebo. “XEOMIN is a promising new option for both patients and physicians and we are encouraged by the response rates seen in the Phase III clinical trials,” says Beverly Hills Dermatologist Derek H. Jones, M.D., an investigator for the U.S. clinical study. Merz says Xeomin will be available worldwide by Spring 2012. Scowl no more!
